{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/venous-eczema-lipodermatosclerosis/management/management/","result":{"pageContext":{"chapter":{"id":"e59690b0-42ea-54b4-8382-b034ef6f16ce","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 9a640369-0fb2-4a14-80ba-a76000c9691a --><h2>Scenario: Management</h2><!-- end field 9a640369-0fb2-4a14-80ba-a76000c9691a -->","summary":"Covers the management of venous eczema and lipodermatosclerosis.","htmlStringContent":"<!-- begin item 6fa9c89d-221a-4349-ae84-a76000c96929 --><!-- begin field c1d7c54a-b5ab-4150-91a7-acbc0157f4de --><p>From age 18 years onwards.</p><!-- end field c1d7c54a-b5ab-4150-91a7-acbc0157f4de --><!-- end item 6fa9c89d-221a-4349-ae84-a76000c96929 -->","topic":{"id":"a90d58ca-80ba-5e1b-aee1-810e3e75187f","topicId":"ea8f06ec-40eb-41f8-9dfd-55c794f27eef","topicName":"Venous eczema and lipodermatosclerosis","slug":"venous-eczema-lipodermatosclerosis","lastRevised":"Last revised in February 2020","chapters":[{"id":"dde62ebe-397a-5a97-a6cc-5be3e33cc5af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c68bfeb8-9972-534c-9530-889987cb5449","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3289083a-63ae-5da0-ac55-7573b0b17e80","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0c543bca-830a-534b-8081-93b33f8b85c4","slug":"changes","fullItemName":"Changes"},{"id":"48b87d07-a723-5292-9ace-293d9160cdc4","slug":"update","fullItemName":"Update"}]},{"id":"26fa0abb-6866-5692-acab-9ac97d7377a2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"759b466b-d727-585b-b067-bd85aa0ff065","slug":"goals","fullItemName":"Goals"},{"id":"df4ffd20-23d7-5bf7-88d8-e064628216cc","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"432518ea-af23-5e82-9821-0e3b3f64d100","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"61c73dfb-a783-5b00-909e-2cae0b88464a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e063dd9a-672b-5aed-8195-115ff345b93c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ee243c9c-f990-522c-8ece-834e1a1625ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a3b857fc-5924-5943-a8ff-aa8801577fd9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2b743c8-8392-5dd2-b5e2-7164cadb1027","slug":"definition","fullItemName":"Definition"},{"id":"7317d644-d2ef-5ab1-8752-8210b1dd55aa","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"f11ac6ce-bfa7-52f0-9949-0450b1dee13a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7c8938f1-30fe-5d79-beb8-bdf649b87db2","slug":"complications","fullItemName":"Complications"},{"id":"c3d84936-e709-5cdb-9f0a-62f8b60ba832","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"e08ced9c-b342-5444-8be4-fe70ab51e86c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6fd54eff-ede5-5162-be02-2b8cdd28af3a","slug":"assessment","fullItemName":"Assessment"}]},{"id":"e758669a-dc76-5648-baa4-05ae63eb3540","fullItemName":"Management","slug":"management","subChapters":[{"id":"e59690b0-42ea-54b4-8382-b034ef6f16ce","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"3f3a5c09-2fc5-59a4-a6cb-6aaffc55117c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"a250fefd-c169-5b73-94f6-d46d48a160a7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bd8d70cc-8839-5f5a-93a6-e5a87374ebcc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"021e369a-1e49-5fe5-bd4a-f7af97404cdc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"87e6498d-2fdf-5fc7-8892-40e897a23461","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"78b755bf-f3ac-5b6a-9e94-9446b45d0828","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5d1768a-5976-5dc9-be51-3aded0ca00df","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a933531e-0f39-56c6-a0c2-95df36dab832","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e758669a-dc76-5648-baa4-05ae63eb3540","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"deaf12fa-2a2b-5026-87bf-85022ef29d06","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field dc3f8a80-2cc2-4005-b685-a76000c9691e --><h3>How should I manage a person with venous skin changes?</h3><!-- end field dc3f8a80-2cc2-4005-b685-a76000c9691e -->","summary":null,"htmlStringContent":"<!-- begin item 10ee5ac6-38f9-487a-849f-a76000c9691e --><!-- begin field 83d193be-7c3c-404f-b4bc-a76000c9691e --><ul><li>​​​​​​<strong>If the person has varicose veins or a venous leg ulcer (active or healed),</strong> see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/varicose-veins/\">Varicose veins</a> and <a class=\"topic-reference external-reference\" href=\"/topics/leg-ulcer-venous/\">Leg ulcer - venous</a> for management information.</li><li><strong>For all other people with venous skin changes:</strong><ul><li><strong>Advise regular application of an emollient, and treat flares with a topical corticosteroid</strong> (flares of lipodermatosclerosis may require application of a very potent topical corticosteroid). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a> for detailed information on the use of emollients and topical steroids, and skin care advice.</li><li><strong>Manage</strong> <strong><a class=\"topic-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/background-information/complications/\">complications</a> where present, such as:</strong><ul><li>Pain — advise the person to take a simple analgesic, such as paracetamol with or without codeine. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> for more information.</li><li>Infection — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a> for detailed information on managing infected eczema. </li><li>Suspected contact dermatitis — refer to a dermatologist for consideration of patch testing.</li></ul></li><li><strong>Give self-care advice to relieve symptoms and reduce the risk of <a class=\"topic-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/background-information/complications/\">complications</a>. </strong>Advise the person to:<ul><li>Avoid injury to the skin as this may lead to ulceration.</li><li>Elevate the legs when resting (for example while sitting in a chair) to help reduce swelling.</li><li>Monitor their skin for signs of damage, paying special attention to skin folds and areas between toes.</li><li>Keep physically active.</li><li>Lose weight, if they are overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li><strong>Consider referral to a vascular service</strong> for symptom control and to prevent disease progression. </li><li><strong>Offer compression stockings </strong>(after <a class=\"topic-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/management/management/#excluding-arterial-insufficiency\">excluding arterial insufficiency</a>). <ul><li>Class 2 (medium) stockings are suitable for most people.</li><li>Try a class 1 (light) stocking if the person cannot tolerate a class 2 stocking.</li><li>Class 3 (strong) stockings may be necessary if the response to a class 2 stocking is inadequate, but many people find these difficult to tolerate.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/compression-stockings/\">Compression stockings</a> for detailed information on the use of compression stockings.</li></ul></li><li><strong>Provide sources of information and advice.</strong><ul><li>The NHS website has information on <a data-hyperlink-id=\"51f7a8b3-765d-4cd4-8094-a98f01883df0\" href=\"https://www.nhs.uk/conditions/varicose-eczema/\">Varicose eczema</a>.</li><li>The National Eczema Society has a factsheet on <a data-hyperlink-id=\"20406deb-94c6-41c5-b4ef-a98f018837c9\" href=\"http://www.eczema.org/varicose-eczema\">Varicose Eczema</a>.</li><li>The British Association of Dermatologists (BAD) has an information leaflet on <a data-hyperlink-id=\"a9043055-1e87-41b2-adc0-a98f018837b4\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=136&itemtype=document\">Venous Eczema</a>.</li></ul></li><li><strong>Refer to a dermatologist </strong>if there is inadequate control of symptoms with primary care management.</li></ul></li></ul><!-- end field 83d193be-7c3c-404f-b4bc-a76000c9691e --><!-- end item 10ee5ac6-38f9-487a-849f-a76000c9691e -->","subChapters":[{"id":"0ee5732d-5817-521c-a7da-a7249d4b575a","slug":"excluding-arterial-insufficiency","fullItemName":"Excluding arterial insufficiency","depth":4,"htmlHeader":"<!-- begin field cc43d05f-bb46-48a9-a660-ab4e0148dd1b --><h4>Excluding arterial insufficiency</h4><!-- end field cc43d05f-bb46-48a9-a660-ab4e0148dd1b -->","summary":null,"htmlStringContent":"<!-- begin item 66d1555d-b11d-48e6-bb06-ab4e0148dc85 --><!-- begin field 12688815-3dfd-41ce-a607-ab4e0148dd1b --><ul><li><strong>It is important to exclude arterial insufficiency before prescribing compression stockings. </strong>If arterial circulation is impaired, compression may further impair the arterial supply and result in pressure damage, limb ischaemia, and amputation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Joint Formulary Committee, 2019</a>].</li><li>Measurement of the ankle brachial pressure index (ABPI) is the most reliable way to detect arterial insufficiency. The absence of foot pulses may indicate arterial insufficiency, but palpation alone is not sufficient to rule this out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">SIGN, 2010</a>].</li><li>The ABPI is the ratio of the ankle systolic blood pressure to the brachial systolic blood pressure and can be measured using a sphygmomanometer and a hand held Doppler device. If the ABPI is [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">SIGN, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Wounds UK, 2019</a>]:<ul><li>Less than 0.5 — severe arterial insufficiency is likely, and compression stockings are contraindicated. The person should be referred urgently for specialist vascular assessment. </li><li>Greater than 0.5 to less than 0.8 — arterial disease or mixed arterial/venous disease is likely. Compression should generally be avoided, but reduced compression can be used under specialist advice and with strict supervision. The person should be referred for specialist vascular assessment. </li><li>Between 0.8 and 1.3 — arterial disease is unlikely, and compression stockings are generally safe to wear.</li><li>Greater than 1.3 — high ABPI values may be due to arterial calcification, such as in some people with diabetes, rheumatoid arthritis, systemic vasculitis, atherosclerotic disease, and advanced chronic renal failure. For values above 1.5, the vessels are likely to be incompressible and the result cannot be relied on to guide clinical decisions. The person should be referred for specialist vascular assessment.</li></ul></li></ul><!-- end field 12688815-3dfd-41ce-a607-ab4e0148dd1b --><!-- end item 66d1555d-b11d-48e6-bb06-ab4e0148dc85 -->","subChapters":[]},{"id":"abcac2f3-9dc5-5e86-a4cd-8de753a036d5","slug":"basis-for-recommendation-689","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8a6bbd85-a456-43a4-8559-a76000c9691e --><h4>Basis for recommendation</h4><!-- end field 8a6bbd85-a456-43a4-8559-a76000c9691e -->","summary":null,"htmlStringContent":"<!-- begin item 68913dbb-1281-4744-95b4-a76000c9691e --><!-- begin field 5b8b0b07-db78-4790-82a8-a76000c9691e --><p>These recommendations are largely based on the Primary Care Dermatology Society (PCDS) guideline <em>Eczema: gravitational eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>] and on expert opinion in review articles on venous skin changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Quartey-Papafio, 1999</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Partsch, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Smith, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Barron et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Middleton, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">DermNet NZ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Duffill, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Hamdan, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Stollery, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Kelechi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">McVittie, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Sundaresan, 2017</a>] and the British Association of Dermatologists (BAD) Patient Information Leaflet on <em>Venous eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">BAD, 2016</a>].</p><h5>Emollients and topical corticosteroids</h5><ul><li>Experts recommend emollients and topical corticosteroids for the management of venous eczema.</li><li>Although the exact pathophysiology of venous eczema is unclear, it is an inflammatory condition and should respond to emollients and topical steroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Quartey-Papafio, 1999</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Smith, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Middleton, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Stollery, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>]. </li><li>Inflamed lipodermatosclerosis can be difficult to treat and may require use of very potent topical steroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Bell, Personal Communication, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Duffill, 2012</a>].</li></ul><h5>Managing complications</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li><li>The recommendation to manage pain is in line with expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">McVittie, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>], one of which states that pain relief may be needed for people with atrophie blanche [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">McVittie, 2015</a>].</li><li>Contact dermatitis commonly occurs in people with venous eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Barron et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Middleton, 2007</a>]. It can be difficult to identify a cause (for example applied topical treatments or a reaction to components of compression stockings), and patch testing may be required.</li></ul><h5>Self-care advice </h5><ul><li>It is thought that leg elevation and exercise may improve venous return and reduce venous pressure, thereby improving the condition of the skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Kelechi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>]. However, there is no trial evidence regarding the benefits of such measures, and it may not be practical for the person to carry them out (for example due to work requirements).</li><li>Expert opinion in a review article is that good skin care is essential in preventing deterioration and ulceration. It is, therefore, important to encourage people with venous skin changes to take an active role in their own skin care by monitoring the skin and caring for it with appropriate products [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>].</li><li>CKS recommends advising on weight loss (if applicable) as being overweight or obese is a possible risk factor for venous insufficiency.</li></ul><h5>Considering referral to a vascular service</h5><ul><li>This recommendation is extrapolated from the National Institute for Health and Care Excellence (NICE) guideline <em>Varicose veins in the legs: The diagnosis and management of varicose veins </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">National Clinical Guideline Centre, 2013</a>]. NICE based these recommendations on evidence from two prognostic reviews, although the evidence was limited in terms of quality and consistency. They are also based on the expert opinion of the NICE guideline development group (GDG). <ul><li>Referral is usually recommended for symptom control and to prevent disease progression.</li><li>People with skin changes due to venous hypertension are at increased risk of developing venous leg ulcers. Therefore, the GDG felt referral was appropriate to plan prophylactic treatment.</li><li>NICE recommends referral to a vascular service, where a full clinical and duplex Doppler ultrasound assessment as well as a full range of treatments can be provided.<ul><li>The NICE GDG highlighted that the location of this service can be decided locally, with some of the service being delivered in primary care where skills and equipment are available.</li><li>The GDG acknowledged that people referred would not necessarily receive interventional treatment but could still benefit from the expertise available from vascular specialists.</li></ul></li></ul></li></ul><h5>Compression stockings </h5><ul><li>Trial data are lacking on the benefits of compression stockings in the management of venous eczema or lipodermatosclerosis. However, it is a widely held view that they improve the condition of the skin by reducing venous hypertension and that they are an important part of the management of venous skin disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Partsch, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Barron et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Duffill, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Hamdan, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Stollery, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Kelechi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">McVittie, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Nazarko, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Sundaresan, 2017</a>].</li></ul><h5>Providing sources of information and advice</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice and is in line with recommendations in the PCDS guideline on gravitational eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">PCDS, 2016b</a>].</li></ul><h5>Referral following primary care treatment</h5><ul><li>Response to management advice is generally good provided there is optimum adherence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">BAD, 2016</a>]. If response is poor despite adequate adherence to management advice, referral to a dermatologist may be necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">Charles, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/references/\">BAD, 2016</a>].</li></ul><!-- end field 5b8b0b07-db78-4790-82a8-a76000c9691e --><!-- end item 68913dbb-1281-4744-95b4-a76000c9691e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}